CSL shares boosted by investment in Australian medical science

13 December 2016
2019_biotech_test_vial_discovery_big

Australian biotech firm CSL Limited (ASX: CSL) has been announced as a co-investor in the government’s Biomedical Translation Fund, developed to stimulate investment in medical science in Australia.

The co-investment will form part of a fund called the Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), in which A$115 million ($86.5 million) of public funds will be matched by the same amount of private investment.

"It’s critical to foster a culture where innovation policies stimulate Australia’s capabilities to facilitate the next generation of breakthrough medicines"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology